Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current CMVLF market cap is 116.52M. The company's latest EPS is USD -2.2029 and P/E is -0.87.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 22.99M | 82.46M | 67.58M | 27.67M | 9.24M |
| Operating Income | -123.55M | -85.44M | -130.68M | -110.85M | -108.2M |
| Net Income | -102.09M | -81.07M | -114.2M | -106.14M | -101.06M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 467.47M | 469.47M | 382.08M | 261.22M | 334.27M |
| Total Liabilities | 112M | 160.63M | 145.6M | 135.28M | 249.58M |
| Total Equity | 355.47M | 308.85M | 236.47M | 125.94M | 84.7M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -69.14M | -80.26M | -104.56M | -87.44M | -24.75M |
| Investing | -35.87M | -54.34M | 7.28M | -2.76M | -15.51M |
| Financing | -3.86M | 27.32M | 47.53M | 1.15M | 82.86M |
| Market Cap | 116.52M |
| Price to Earnings Ratio | -0.87 |
| Price to Sales Ratio | 9.48 |
| Price to Cash Ratio | 0.64 |
| Price to Book Ratio | 1.03 |
| Dividend Yield | - |
| Shares Outstanding | 45.87M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | -11.19% |
| 52 Week High | 3.58 |
| 52 Week Low | 2.35 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Cellectis (CE) |
| Address |
8 rue de la croix- jarry paris, paris 75013 |
| Website | https://www.cellectis.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
